Learn More
Recent studies have shown some degrees of discordance in ER, PR and HER-2 immunohistochemical expression between primary and recurrent/metastatic lesions (RML). Analysis was made on 78 patients with MBC whose ER, PR and/or HER-2 status were known both on the tissue samples of primary and RML. Among the RML sites, 29.5% were locoregional, 70.5% were distant(More)
It has been reported previously that: (1) normal-breast epithelial cells that are CD24-/44+ express higher levels of stem/progenitor cell-associated genes; (2) cancer cells that have undergone epithelial to mesenchymal transition display CD24-/44+ cell-surface expression, a marker for breast cancer stem cells; (3) loss of E-cadherin is a preliminary step in(More)
IMPORTANCE OF THE FIELD Hormone and human epidermal growth factor receptor 2 (HER-2) receptors are two important pharmaceutical targets that affect the survival of patients with metastatic breast cancer. Discordance of hormone and HER-2 receptors were reported in a series of studies. Receptor status was reported to change in both directions, yet alteration(More)
To The Editor, We read with great interest the article by Torrisi et al. [2]. In their preoperative treatment of locally advanced triple negative breast cancer, cisplatin containing chemotherapy followed by paclitaxel induced a high pCR rate. Authors in the discussion part state that their results support lower responsiveness to taxanes if compared with(More)
In their interesting paper, Chekmariova et al. [1] found potentially high clinical relevance of CHEK2 1100delC in breast cancer patients of Russian origin. However, they did not mention clinical-pathological characteristics of these breast cancer patients with CHEK2 1100delC. Similar to BRCA1, CHEK2 is a tumor suppressor and acts in response to DNA double(More)
  • 1